ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemo-attractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing shareholder value.
4:00 PM ET on Aug 28, 2015
Delayed at least 20 minutes.
Provided by eSignal.
Aug 6, 2015
ChemoCentryx Reports Second Quarter 2015 Financial Results and Provides Corporate Update
Jul 30, 2015
ChemoCentryx Announces Changes to its Board of Directors
Jul 29, 2015
ChemoCentryx to Hold Second Quarter 2015 Financial Results Conference Call on Thursday, August 6, 2015
^ Return to Top